NBCoV1 is a highly potent small molecule viral fusion inhibitor with potential pan-Coronavirus activity (SARS-CoV IC50=17 nM, SARS-CoV-2 IC50=51 nM, MERS-CoV IC50=75 nM, cell-based single-cycle assays).

NBCoV2 is a highly potent small molecule viral fusion inhibitor with potential pan-Coronavirus activity (SARS-CoV IC50=13.8 nM, SARS-CoV-2 IC50=22.8 nM, MERS-CoV IC50=77 nM, cell-based single-cycle assays). NBCoV2 also has potent antiviral activity against all mutant pseudoviruses carrying single-, double-, or triple-mutations featured in the B.1.1.7 UK, B.1.351 RSA, and B.1.617.2 Delta variants (IC50=30-80 nM). NBCoV2 completely preventing the induction of any virus-induced CPE (IC100=1.25 uM, SARS-CoV-2 (US_WA-1/2020)). NBCoV2 bind to the S2 subdomain of the SARS-CoV-2 trimer, thus, inhibits the fusion of CoVs with the cell membran, and is specific for the SARS-CoV-2 S protein.

NSC 621601 (Compound Q34) is a potent, specific inhibitor of SARS-CoV-2 cellular entry with IC50 of 15 uM.

Olgotrelvir (STI-1558) is a next-generation antiviral targeting SARS-CoV-2 Mpro and host lysosomal cysteine protease cathepsin L (CTSL) with high antiviral activity, Olgotrelvir is the prodrug of AC1115.

P2119 (P-2119) is an anticoronaviruse chemical probe that inhibit SARS-CoV-2 Spike binding to human ACE2 receptor.

P2165 (P-2165) is a anticoronaviruse chemical probe that inhibit SARS-CoV-2 Spike binding to human ACE2 receptor.

PAV-104 (PAV104) is a novel viral assembly inhibitor, shows potent anti-SARS-CoV-2 activity in Calu-3 cells with EC50 of 1.7 nM and EC90 of 23.5 nM, inhibits the oligomerization of the SARS-CoV-2 nucleocapsid.

Pomotrelvir (PBI-0451) is a potent competitive inhibitor of SARS-CoV-2 Mpro (Ki=2.7 nM) with high selectivity against human proteases, inhibits wild-type SARS-CoV-2 Mpro with IC50 of 24 nM.

SB27012 (SB 27012) is a small molecule PPI inhibitor of the Spike RBD-ACE2 interaction (IC50=7.7 uM in ELISA assays), binds ACE2 (Kd=210 nM) without affecting ACE2 enzymatic activity.

SCoV2 Plpro-Probe-7 is a peptidomimetic activity probe and substrate for SCoV2 PLpro, exhibits excellent sensitivity to wild-type (WT) SCoV2 PLpro, but not to the catalytically inactive mutant, SCoV2 PLproC112S, consists of a fluorogenic HCC conjugated to

Simnotrelvir (SSD8432, SIM0417) is a potent, selective, covalent and orally bioavailable SARS-CoV-2 3C-like protease (3CLpro) inhibitor with IC50 of 9 nM in enzymatic inhibition assays.

Titanocene dichloride (Cp2 TiCl 2) is an active inhibitor of interaction between SARS-CoV-2 spike (S) protein with the ACE2 receptor (IC50=3.9 uM)

TKB245 (TKB-245) is a potent, specific SARS-CoV-2 Mpro inhibitor with IC50 of 7 nM, exhibits highly potent anti-SARS-CoV-2 activity with EC50 and EC95 values of 0.03 and 0.53 µM, respectively.

TKB248 (TKB-248) is a potent, specific SARS-CoV-2 Mpro inhibitor with IC50 of 74 nM, exhibits highly potent anti-SARS-CoV-2 activity with EC50 and EC95 values of 0.22 and 0.87 µM, respectively.

VE607 is a specific small molecule inhibitor that block S protein-ACE2-mediated cellular entry of the SARS-CoV, inhibits pseudovirus entry with EC50 of 3 μM and inhibited SARS-CoV plaque formation with EC50 of 1.6 μM.

WNN2048-F004 (Compound 4a) is a potent, covalent, nonpeptidomimetic SARS-CoV-2 main protease (Mpro) inhibitor with biochemical IC50 of 103 nM, covalently binds to the substrate-binding pocket (Cys145) of SARS-CoV-2 Mpro.

WU-04 is a highly potent, non-covalent, orally active inhibitor of SARS-CoV-2 3C-like protease (3CLpro) with IC50 of 72 nM, binding Kd of 37 nM.

Y180 is a highly potent, selective, covalent, and orally active SARS-CoV-2 main protease (Mpro) inhibitor with IC50 of 8.1 nM in enzymatic assays, binding Ki value of 1 nM.

Z222979552 is a small molecule non-covalent SARS-CoV-2 Mpro inhibitor with IC50 of 1.0 uM.

Z8539_0072 is a potent SARS-CoV-2 macrodomain inhibitor that binds to the NSP3 macrodomain of SARS-CoV-2 (Mac1) with IC50 of 460 nM.

EIDD-1931 (Beta-d-N4-hydroxycytidine, β-d-N4-hydroxycytidine, NHC) is an active metabolite of EIDD-2801 with broad-spectrum antiviral inhibitor of SARS-CoV-2.

NSC89641 inhibits MERS-CoV Mpro, with an IC50 value < 3.5 μM. NSC89641 exhibits the high inhibitory potency against SARS-CoV-2 Mpro enzymatic activity, with an IC50 of 3.05 μM.